Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32823168&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis #MMPMID32823168
Fang Y; Ye J; Zhao B; Sun J; Gu N; Chen X; Ren L; Chen J; Cai X; Zhang W; Yang Y; Cao P
Redox Biol 2020[Sep]; 36 (?): 101677 PMID32823168show ga
Management of oxaliplatin-induced peripheral neuropathy (OIPN) has proven challenging owing to the concern that any OIPN-preventing agents may also decrease the efficacy of the chemotherapeutic agent and fail to reverse established neuronal damage. Nevertheless, targeting redox signaling pathways constitutes a promising therapy in OIPN and we have previously demonstrated the protective role of nuclear factor erythroid-2 related factor 2 (NRF2) in this disorder. Here, we investigated the protective properties of formononetin (FN), a clinical preparation extract, in OIPN. RNA interference experiments revealed that FN protects against OIPN directly through activation of the NRF2 pathway. Further expression profile sequencing showed that FN exerts its protective effect via the NRF2 downstream-oxaliplatin metabolism enzyme, GSTP1. We also demonstrated that FN does not influence the chemotherapeutic function of oxaliplatin, as NRF2 exhibits a different drug metabolic enzyme activation state downstream in colorectal cell lines than that in neurons. Following synthesis of Bio-FN to screen the target binding proteins, we found that FN selectively binds to His129 and Lys131 in the BTB domain of KEAP1. In vivo experiments revealed that FN-induced activation of the NRF2 signaling pathway alleviated the nociceptive sensations in mice. Our findings highlight a new binding mechanism between KEAP1 and isoflavones for activation of the NRF2 system and suggest that pharmacological or therapeutic activation of the NRF2-GSTP1 axis may serve as an effective strategy to prevent or attenuate the progression of OIPN.
|*Isoflavones/pharmacology[MESH]
|*Peripheral Nervous System Diseases/chemically induced/drug therapy/genetics[MESH]
|Animals[MESH]
|Kelch-Like ECH-Associated Protein 1/genetics[MESH]
free
free
free
Redox+Biol 2020 ; 36 (?): 101677
